Wells Fargo analyst Benjamin Burnett raised the firm’s price target on Xenon Pharmaceuticals (XENE) to $69 from $68 and keeps an Overweight rating on the shares. The firm sees a high probability of approval of azetukalner in focal onset seizures. However, Praxis Precision’s (PRAX) Phase 3 vormatrigine POWER1 data creates some near term risk for Xenon, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XENE:
- Xenon Pharmaceuticals Maps Path After Standout XTOL-2
- Xenon Pharmaceuticals price target lowered to $78 from $80 at Needham
- Analyst Reaffirms Buy on Xenon, Citing Blockbuster Potential for Lead Epilepsy Candidate and Upside from Pipeline Programs
- Xenon Highlights Positive Phase 3 Azetukalner Seizure Data
- Xenon Pharmaceuticals reports Q1 EPS ($1.17), consensus ($1.20)